Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP286369.RA9jNlIRe4r4vMQ2YCghMtybvc-5pDx1b-mW8xnNAeMfA130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP286369.RA9jNlIRe4r4vMQ2YCghMtybvc-5pDx1b-mW8xnNAeMfA130_assertion type Assertion NP286369.RA9jNlIRe4r4vMQ2YCghMtybvc-5pDx1b-mW8xnNAeMfA130_head.
- NP286369.RA9jNlIRe4r4vMQ2YCghMtybvc-5pDx1b-mW8xnNAeMfA130_assertion description "[We examined clinicopathologic features of the urinary tract LELC, including light microscopy; immunohistochemistry for cytokeratin 7 (CK7), CK20, 34?E12, p53, p63, ?-methylacyl-CoA racemase, thyroid transcription factor-1, Epstein-Barr virus latent membrane protein-1, and CD30; in situ hybridization for human papillomavirus; and UroVysion fluorescence in situ hybridization (FISH).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP286369.RA9jNlIRe4r4vMQ2YCghMtybvc-5pDx1b-mW8xnNAeMfA130_provenance.
- NP286369.RA9jNlIRe4r4vMQ2YCghMtybvc-5pDx1b-mW8xnNAeMfA130_assertion evidence source_evidence_literature NP286369.RA9jNlIRe4r4vMQ2YCghMtybvc-5pDx1b-mW8xnNAeMfA130_provenance.
- NP286369.RA9jNlIRe4r4vMQ2YCghMtybvc-5pDx1b-mW8xnNAeMfA130_assertion SIO_000772 21383609 NP286369.RA9jNlIRe4r4vMQ2YCghMtybvc-5pDx1b-mW8xnNAeMfA130_provenance.
- NP286369.RA9jNlIRe4r4vMQ2YCghMtybvc-5pDx1b-mW8xnNAeMfA130_assertion wasDerivedFrom befree-20140225 NP286369.RA9jNlIRe4r4vMQ2YCghMtybvc-5pDx1b-mW8xnNAeMfA130_provenance.
- NP286369.RA9jNlIRe4r4vMQ2YCghMtybvc-5pDx1b-mW8xnNAeMfA130_assertion wasGeneratedBy ECO_0000203 NP286369.RA9jNlIRe4r4vMQ2YCghMtybvc-5pDx1b-mW8xnNAeMfA130_provenance.